419eP 7-y survival in patients (pts) with extended-stage small cell lung cancer (ES-SCLC) treated with atezolizumab (atezo) in the IMpower133 (IMp133) and IMbrella A extension study, including brain (BM) and liver metastases (LM) by SCLC molecular subtype
Year: 2026
Type: article
Abstract: IMp133 (NCT02763579) showed that first-line (1L) atezo + carboplatin/etoposide (A+CE) improved outcomes vs placebo + CE (P+CE) in ES-SCLC. IMbrella A (NCT03148418) is an open-label, single-arm, observational extension of IMp133. Molecular subtypes of SCLC are defined by transcription factors ASCL1 (SCLC-A) and NEUROD1 (SCLC-N) and inflamed subsets with neuroendocrine (SCLC-I-NE) or non-neuroendocrine (SCLC-I-nNE) features. We report IMbrella A data (clinical cutoff date [CCOD]: 18 Dec 2025) including pts with overall survival (OS) ≥84 mo and molecular subtypes of pts with BM and LM from IMp133.
Source: ESMO Open
Institutions: LungenClinic Grosshansdorf, Gdańsk Medical University, Sendai Kousei Hospital, Chris O’Brien Lifehouse, Wiener Krankenanstaltenverbund, Ludwig Boltzmann Institute for Lung Health, Instituto do Câncer do Estado de São Paulo, Hospital Universitario Virgen del Rocío, Seoul National University Bundang Hospital, The Maria Sklodowska-Curie National Research Institute of Oncology, University Hospital Medical Center Bezanijska kosa, F. Hoffmann-La Roche AG, Genentech, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,910
Funder: Roche
OpenAlex ID: W7138330767